the bear case... SGMO has less than a 1 year cash runway and there are no potential positive catalysts until 2H2024, the viability of which are very suspect

the bull case... the ATM will provide the necessary financing bridge until some break-through clinical achievement will validate Sangamo and its viability... the SP will spike and it will be all blue skies ahead !

my projection... ~$2.50 SP after the next ER/CC in late Feb... and then the death spiral begins :-(

but what say you MartyC, bct1192, or Bioimmuno :-)